Cervical Cancer Clinical Trials in New York, New York
13 studies are recruiting for cervical cancer in New York, New York right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.
Search these by distance from you
Studies now recruiting
-
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma [cutaneous/acral], squamous cell carcinomas of the head and neck (SCCHN), HER2-negative gastric can…
- Stage
- Phase 2
- Ages
- 18 and older
- Site
- Memorial Sloan Kettering Hospital, New York, New York
- Locations
- 90 in total
- Run by
- Daiichi Sankyo
-
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
Researchers are looking for new ways to treat metastatic cervical cancer. Cervical cancer is cancer in the cervix, the lower part of the uterus (womb). Metastatic means the cancer has spread to other parts of the body. Researchers want to learn about giving the study medicine sacituzumab tirumoteca…
- Stage
- Phase 3
- Ages
- 18 and older
- Site
- Laura and Isaac Perlmutter Cancer Center at NYU Langone ( Site 6009), New York, New York
- Locations
- 174 in total
- Run by
- Merck Sharp & Dohme LLC
-
GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-101/GI-101A as a single agent or in combination with pembrolizumab or lenvatinib over a range of advanced and/or metastatic solid tumors.
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- Tisch Cancer Institute (TCI), Icahn School of Medicine, New York, New York
- Locations
- 13 in total
- Run by
- GI Innovation, Inc.
-
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-M07D1 in patients with HER2 expressing advanced tumors.
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York, New York
- Locations
- 26 in total
- Run by
- SystImmune Inc.
-
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-…
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- NYU Langone Medical Center - Perlmutter Cancer Center (NYU Cancer Institute), New York, New York
- Locations
- 39 in total
- Run by
- Eli Lilly and Company
-
Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer
TIVDAK is used for the treatment of cervical cancer that has come back after chemotherapy. Chemotherapy is a treatment that uses medicines to stop the growth of cancer cells. This is done either by killing the cells or by stopping them from growing. The purpose of this study is to learn about possi…
- Stage
- Phase 4
- Ages
- 18 and older
- Site
- Columbia University Medical Center - Herbert Irving Pavilion, New York, New York
- Locations
- 130 in total
- Run by
- Pfizer
-
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
This is a study to evaluate the safety and preliminary anti-tumor activity of STRO-004 in adults with metastatic cancer. This study includes 3 parts: * Part 1A is a dose escalation study of STRO-004 monotherapy in selected tumor types known to commonly express Tissue Factor (TF). * Part 1B is a coh…
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York
- Locations
- 9 in total
- Run by
- Sutro Biopharma, Inc.
-
A Study of Ivonescimab in People With Endometrial and Cervical Cancers
The researchers are doing this study to find out if ivonescimab is an effective treatment for people with endometrial cancer (EC) and/or cervical cancer (CC). The researchers will also look at whether the study drug is safe and causes few or mild side effects in participants.
- Stage
- Phase 2
- Ages
- 18 and older
- Site
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York
- Locations
- 7 in total
- Run by
- Memorial Sloan Kettering Cancer Center
-
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab, docetaxel, or Pumitamig in participants with advanced solid tumors. This study is a first-in-human (FIH) study of BMS-986340 in participants with …
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- Local Institution - 0006, New York, New York
- Locations
- 47 in total
- Run by
- Bristol-Myers Squibb
-
A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer
This is a randomized controlled trial to compare survival for patients who undergoe robotic assisted laparoscopy versus open hysterectomy and lymph node assessment for the treatment of early stage cervical cancer.
- Stage
- Not phased
- Ages
- 18 and older
- Site
- Laura and Issac Perlmutter Cancer Center at NYU Langone-East 34th Street, New York, New York
- Locations
- 156 in total
- Run by
- GOG Foundation
-
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors.
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- Memorial Sloan Kettering Cancer Center Head Neck Services, New York, New York
- Locations
- 39 in total
- Run by
- SystImmune Inc.
-
Circulating Human Papilloma Virus (HPV) DNA for the Screening and Surveillance of Gynecologic Cancers
Human papilloma virus-related gynecologic malignancies affect over 20,000 women in the United States, and over half a million women globally each year. In addition, approximately 200,000 women are diagnosed with high-grade cervical dysplasia, a pre-cancerous tumor. There is no currently available s…
- Stage
- Not phased
- Ages
- 18 and older
- Site
- Lenox Hill Hospital, New York, New York
- Run by
- Northwell Health
-
NYSCF Scientific Discovery Biobank
The New York Stem Cell Foundation (NYSCF) Research Institute is performing this research to accelerate diverse disease research using cells from the body (such as skin or blood cells) to make stem cells and other types of cells, conduct research on the samples, perform genetic testing, and store th…
- Stage
- Not phased
- Ages
- 0 and older
- Site
- New York Stem Cell Foundation Research Institute, New York, New York
- Run by
- New York Stem Cell Foundation Research Institute
How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.
What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.
Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.